Mostefa Bennamoun

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 128 citations · Full text

Urology, Oncology, Genitourinary Cancer +7

Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma

Guillaume Davidson, Alexandra Helleux, Yann Vano et al. · Cancer Research · 2023 · 74 citations

<scp>PEPCOL</scp>: a <scp>GERCOR</scp> randomized phase <scp>II</scp> study of nanoliposomal irinotecan <scp>PEP</scp>02 (<scp>MM</scp>‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Jean‐Baptiste Bachet et al. · Cancer Medicine · 2016 · 47 citations · Full text

LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

Yann Vano, R.T. Elaidi, Mostefa Bennamoun et al. · Annals of Oncology · 2020 · 29 citations

Lba25 Results, Urology, Bionikk Trial +7

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

Charles Vauchier, Édouard Auclin, Philippe Barthélémy et al. · Journal of Oncology · 2022 · 28 citations · Full text